JP2002511411A5 - - Google Patents

Download PDF

Info

Publication number
JP2002511411A5
JP2002511411A5 JP2000543134A JP2000543134A JP2002511411A5 JP 2002511411 A5 JP2002511411 A5 JP 2002511411A5 JP 2000543134 A JP2000543134 A JP 2000543134A JP 2000543134 A JP2000543134 A JP 2000543134A JP 2002511411 A5 JP2002511411 A5 JP 2002511411A5
Authority
JP
Japan
Prior art keywords
cannabidiol
active ingredient
treating
agent
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000543134A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002511411A (ja
Filing date
Publication date
Priority claimed from GBGB9807639.1A external-priority patent/GB9807639D0/en
Application filed filed Critical
Publication of JP2002511411A publication Critical patent/JP2002511411A/ja
Publication of JP2002511411A5 publication Critical patent/JP2002511411A5/ja
Pending legal-status Critical Current

Links

JP2000543134A 1998-04-14 1999-04-14 抗炎症剤 Pending JP2002511411A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9807639.1 1998-04-14
GBGB9807639.1A GB9807639D0 (en) 1998-04-14 1998-04-14 Anti-inflammatory agents
PCT/GB1999/001140 WO1999052524A1 (en) 1998-04-14 1999-04-14 Use of cannabinoids as anti-inflammatory agents

Publications (2)

Publication Number Publication Date
JP2002511411A JP2002511411A (ja) 2002-04-16
JP2002511411A5 true JP2002511411A5 (https=) 2006-05-18

Family

ID=10830115

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000543134A Pending JP2002511411A (ja) 1998-04-14 1999-04-14 抗炎症剤

Country Status (12)

Country Link
US (1) US6410588B1 (https=)
EP (1) EP1071417B1 (https=)
JP (1) JP2002511411A (https=)
AT (1) ATE288749T1 (https=)
AU (1) AU757945B2 (https=)
CA (1) CA2328368C (https=)
DE (1) DE69923671T2 (https=)
DK (1) DK1071417T3 (https=)
ES (1) ES2241277T3 (https=)
GB (1) GB9807639D0 (https=)
IL (1) IL138979A0 (https=)
WO (1) WO1999052524A1 (https=)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU766988B2 (en) 1998-04-21 2003-10-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Cannabinoids as antioxidants and neuroprotectants
BR0009200A (pt) 1999-03-22 2001-12-26 Immugen Pharmaceuticals Inc Compostos e composições para o tratamento dedoenças associada com disfunção imune
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
ES2256305T3 (es) * 2000-10-31 2006-07-16 Pharma Mar, S.A. Formulaciones de kahalalide f.
EP1206934A1 (en) * 2000-11-15 2002-05-22 B. Braun Melsungen Ag Blockade of sodium channels by phenol derivatives
US10004684B2 (en) 2001-02-14 2018-06-26 Gw Pharma Limited Pharmaceutical formulations
GB0202385D0 (en) * 2002-02-01 2002-03-20 Gw Pharma Ltd Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions
EP1482917B1 (en) * 2002-02-01 2019-05-08 GW Pharma Limited Compositions comprising cannabidiolic acid for treatment of nausea, vomiting, emesis, motion sickness or like conditions
IL148244A0 (en) 2002-02-19 2002-09-12 Yissum Res Dev Co Anti-nausea and anti-vomiting activity of cannabidiol compounds
AU2003217961B2 (en) 2002-03-08 2008-02-28 Signal Pharmaceuticals, Llc Combination therapy for treating, preventing or managing proliferative disorders and cancers
SI1542657T1 (sl) * 2002-08-14 2012-04-30 Gw Pharma Ltd Kanabinoidne kapljevite formulacije za sluzniäśno administracijo
US7067155B2 (en) * 2003-01-03 2006-06-27 Tbni, Inc. Anti-inflammatory humate compositions and methods of use thereof
IL160420A0 (en) * 2004-02-16 2004-07-25 Yissum Res Dev Co Treating or preventing diabetes with cannabidiol
WO2006024958A2 (en) * 2004-08-09 2006-03-09 Novimmune S.A. Cannabinoid compositions and methods of use thereof
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
US20100158973A1 (en) 2006-03-13 2010-06-24 Hadasit Medical Research Services & Development Llimited Therapeutic uses of cannabidiol compounds
GB2438682A (en) * 2006-06-01 2007-12-05 Gw Pharma Ltd New use for cannabinoids
GB2448535A (en) * 2007-04-19 2008-10-22 Gw Pharma Ltd New use for cannabinoid-containing plant extracts
GB2450741A (en) * 2007-07-05 2009-01-07 Gw Pharma Ltd Cannabinoid containing plant extracts in the treatment of inflammatory bowel disease
ES2359168T3 (es) * 2007-10-02 2011-05-19 Vivacell Biotechnology España S.L. Composición que comprende cannabinoides no psicotrópicos para el tratamiento de enfermedades antiinflamatorias.
GB2496688B (en) 2011-11-21 2016-06-29 Gw Pharma Ltd Tetrahydrocannabivarin for use in the treatment of intestinal inflammatory diseases
US9956182B2 (en) 2013-05-02 2018-05-01 Mor Research Applications Ltd. Cannabidiol for the prevention and treatment of graft-versus-host disease
US9889100B2 (en) 2013-05-02 2018-02-13 Mor Research Applications Ltd. Cannabidiol for treatment of severe and refractory graft-versus-host disease
US10172786B2 (en) * 2014-12-16 2019-01-08 Axim Biotechnologies, Inc. Oral care composition comprising cannabinoids
EP3277260B1 (en) 2015-04-01 2021-05-12 The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) Erodium crassifolium l'her plant extracts and uses thereof
US12303541B2 (en) 2015-04-01 2025-05-20 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Erodium crassifolium L'Her plant extracts and uses thereof
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
WO2017066747A1 (en) * 2015-10-16 2017-04-20 Scythian Biosciences Inc. Methods and compositions for treating gastrointestinal inflammation
WO2017160923A1 (en) * 2016-03-15 2017-09-21 Royal Oil Colorado Llc Formulations of argan oil and cannabidiol
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
US10399920B2 (en) 2016-06-01 2019-09-03 S&B Pharma, Inc. Crystalline form of cannabidiol
GB2551985B (en) * 2016-07-01 2019-01-30 Gw Res Ltd Novel formulation
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
WO2018064654A1 (en) 2016-10-01 2018-04-05 James Smeeding Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof
EP3534893A1 (en) 2016-11-02 2019-09-11 To Pharmaceuticals LLC Combination therapy of cbd and copaxone
EP3592346A4 (en) 2017-03-05 2020-12-30 The State of Isreal, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
WO2019014851A1 (zh) * 2017-07-18 2019-01-24 汉义生物科技(北京)有限公司 大麻二酚在治疗肺动脉高压中的应用
IL301622A (en) * 2017-08-14 2023-05-01 Zynerba Pharmaceuticals Inc Methods for treating degenerative joint disease with cannabidiol gel through the skin
US11110056B1 (en) 2018-05-03 2021-09-07 Actual Natural Health & Wellness Products, Inc. Nasal hygiene method and composition
US10945982B1 (en) * 2018-05-03 2021-03-16 Paul A. Lobel Nasal hygiene method and composition
JP2021526556A (ja) 2018-05-30 2021-10-07 ダイレクト バイオロジクス エルエルシー 成長因子および細胞外小胞を凍結または粉状にした、間葉系幹細胞(msc)の調製物を含む助剤、ならびにその使用方法
EP3866781A4 (en) * 2018-10-16 2022-11-09 Systamedic Inc. NOVEL COMPOSITION FOR THE TREATMENT OF INFLAMMATORY DISEASES
US11026888B1 (en) 2019-01-04 2021-06-08 Nutrition Therapeutics, Inc. Functional beverage compositions and methods of using and making same
AU2019424226B2 (en) * 2019-01-24 2023-06-29 Hanyi Bio-Technology Company Ltd. Use of geranylflavone A in preparation of drug for promoting healing of wounds
BR112021015549A2 (pt) 2019-02-07 2021-10-26 Direct Biologics Llc Método para tratar osteoartrite com uma combinação de exossomos de células tronco mesenquimais, células tronco mesenquimais sinoviais e andaimes
WO2020167751A1 (en) * 2019-02-11 2020-08-20 Chancey John Methods of making and using phytocannabinoids complexed with a protein, peptide, amino acid, polysaccharide, disaccharide, ormonosaccharide
WO2020223510A1 (en) * 2019-04-30 2020-11-05 Greenway Herbal Products, Llc Cannabinoid compositions and methods of using
CA3146433A1 (en) 2019-07-18 2021-01-21 Direct Biologics Llc Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use
AU2021250462A1 (en) * 2020-04-02 2022-12-01 Incannex Healthcare Limited Methods and compositions for treating or preventing an inflammatory condition
US12590310B2 (en) 2020-04-22 2026-03-31 Direct Biologics, Llc Methods and compositions for treating inflammatory conditions associated with infectious disease
IL298062A (en) * 2020-05-11 2023-01-01 Add Advanced Drug Delivery Tech Ltd Uses and formulations of cannabinoids
IL298059A (en) * 2020-05-11 2023-01-01 Add Advanced Drug Delivery Tech Ltd Uses and formulations of cannabinoids
CA3199891A1 (en) 2020-11-24 2022-06-02 Ruth Gallily Cannabinoid derivatives and their use for the treatment of inflammation and/or pain and/or obesity
IL309886A (en) * 2021-07-15 2024-03-01 Incannex Healthcare Ltd A preparation containing cannabidiol and hydroxychloroquine in a combined capsule at a fixed dose
WO2023096918A1 (en) * 2021-11-27 2023-06-01 Miralogx Llc Synthetic cannabinoid compounds, pharmaceutical compositions, and treatment methods
CA3244798A1 (en) 2022-02-21 2023-08-24 Universidade Nova De Lisboa COMPOUNDS AND COMPOSITIONS AGAINST NEURODEGENERATIVE DISEASES
EP4230201A1 (en) 2022-02-21 2023-08-23 Universidade Nova De Lisboa Composition for treating neurodegenerative diseases
WO2024033521A1 (en) 2022-08-12 2024-02-15 GW Research Limited Oral solid dosage forms comprising cannabinoids
US12502407B2 (en) 2024-04-25 2025-12-23 Direct Biologics, Llc Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles
WO2025259202A1 (en) * 2024-06-12 2025-12-18 Chiang Mai University A method of reprogramming human somatic cells and reprogrammed cells derived thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL48824A (en) 1976-01-12 1980-05-30 Yissum Res Dev Co Pharmaceutical compositions containing (3s,js) tetrahydrocanabinol derivatives and some novel compounds of this type
US4847290A (en) * 1987-08-17 1989-07-11 Sumner Burstein Delta 1-thc-7-oic acid and analgesic and anti-inflammatory agents
US4973603A (en) * 1988-06-16 1990-11-27 Sumner Burstein Platelet activating factor antagonist and methods of use therefor
US5521215A (en) * 1989-11-07 1996-05-28 Ramot University Authority For Applied Research And Industrial Development Ltd. NMDA-blocking pharmaceuticals
US5338753A (en) * 1992-07-14 1994-08-16 Sumner H. Burstein (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics

Similar Documents

Publication Publication Date Title
JP2002511411A5 (https=)
NO2025027I1 (no) Pharmaceutical mixture or association that includes as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof - forlenget.
NO2017047I1 (no) Tofacitinib, evt. i form av et farmasøytisk akseptabelt salt, inkludert citratsalt
CA2386690A1 (en) Pharmaceutical tramadol salts
JP2004525194A5 (https=)
WO2000041681A3 (de) ARZNEIFORMULIERUNGEN ENTHALTEND EIN OPIOID UND EINEN α-AGONISTEN
DK1183014T3 (da) Smagsmaskerede orale farmaceutiske sammensætninger med kontrolleret frigivelse
JP2002506648A5 (https=)
ATE259798T1 (de) Pharmazeutisch aktive verbindungen
ITMI20001173A0 (it) Composizioni farmaceutiche a rilascio prolungato per la somministrazione parenterale di sostanze idrofile biologicamente attiva.
ZA200202521B (en) 2'-substituted 1,1'-biphenyl-2-carbonamides, method for the production thereof, use thereof as a medicament and pharmaceutical preprations containing said compounds.
CA2326222A1 (en) Medicinal compositions
ZA200000169B (en) Process for the preparation of pellets with a content of up to 90 wt.% of a pharmaceutical active ingredient.
CY2347B1 (en) Matrix tablet enabling the prolonged release of trimetazidine after administration by the oral route.
JP2000159790A5 (https=)
ATE252377T1 (de) Kontrolliert freisetzende pharmazeutische zusammensetzung mit tilidinmesylat als wirkstoff
HUP0400155A3 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
HK1046631A1 (zh) 含有酮替芬的眼药组合物
JP2001513504A5 (https=)
MXPA02001575A (es) Agente farmaceutico que comprende un derivado de benzamida como un ingrediente activo.
AU1650501A (en) 1,3,4-oxadiazoline derivatives and drugs containing these derivatives as the active ingredient
DE59102620D1 (de) Feste orale Applikationsformen, die als Wirkstoff Ifosfamid enthalten.
EP1132087A4 (en) REMEDIES FOR POLYKYSTIC OVARY SYNDROME
JP2002531135A5 (https=)
JP2006527741A5 (https=)